首頁 > 市場調查報告書 > 製藥

感染疾病呼吸器

市場調查報告書

商品編碼

2039009

社區型細菌性肺炎 (CABP) 治療市場：按藥物類別、劑型、給藥途徑、分銷管道和地區分類

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, By Dose Form, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月30日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年社區型細菌性肺炎（CABP）治療市場規模估計為19.268億美元，預計2033年將達到32.076億美元。預計2026年至2033年，該市場將以7.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	19.268億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.70%	2033年市場規模預測：	32.076億美元

社區型細菌性肺炎（CABP）是各種可能導致敗血症的感染疾病中最常見的急性呼吸道疾病。從微生物學角度來看，細菌是肺炎的常見病原體，其中肺炎鏈球菌是全球最常見的致病菌。 CABP是導致疾病和住院的最常見感染疾病，尤其是在老年族群。例如，根據美國國家生物技術資訊中心（NCBI）的數據，截至2020年3月，美國每年有超過500萬例社區型肺炎（CAP）病例。

市場動態

大型製藥公司採取的非個人化策略正在鞏固其在全球社區型細菌性肺炎（CABP）治療市場的佔有率。例如，2017年，RIVA集團旗下子公司Avir Pharma Inc.（Avir）與Basilea Pharmaceutica Ltd.達成銷售和授權合約，授權其在加拿大銷售抗真菌藥物Cresemba（Isavuconazole）和抗生素Zevtera（頭孢吡肟）。 Avir計畫申請Isavuconazole在加拿大的上市核准。 Zevtera已獲得加拿大衛生署核准，用於治療成人醫院獲得性肺炎（HAP）和社區獲得性肺炎（CAP），Avir計劃從Basilea採購該產品並在加拿大銷售。

然而，抗藥性細菌的出現正在阻礙市場成長。例如，根據美國國家生物技術資訊中心（NCBI）2019年11月發表的報導，即使肺炎球菌對BETA-內醯胺類抗生素仍然敏感，單用BETA-內醯胺類抗生素治療肺炎球菌性肺炎也可能不是最佳治療方法。因此，抗生素抗藥性預計將抑制全球社區獲得性細菌性肺炎（CABP）治療市場的發展。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新藥上市和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的關鍵見解。
本研究根據以下參數對全球社區獲得性細菌性肺炎 (CABP) 治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、市場佔有率、分銷策略、主要發展、戰略和未來計劃。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的藥物上市、藥物類別升級、市場擴張和行銷策略做出明智的決策。
《全球社區獲得性細菌性肺炎 (CABP) 治療市場》報告的目標受群眾外包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師等行業利益相關相關人員。
相關人員可以透過利用分析全球社區型細菌性肺炎 (CABP) 治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第9章競爭情勢

熱圖分析
市佔率分析
- Nabriva Therapeutics
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals, Inc.
- Mylan NV
- Sanofi SA
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG

第10章

參考
調查方法

簡介目錄

Product Code: CMI4269

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market is estimated to be valued at USD 1,926.8 Mn in 2026 and is expected to reach USD 3,207.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,926.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.70%	2033 Value Projection:	USD 3,207.6 Mn

Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.

Market Dynamics

Inorganic strategies amongst key players are strengthening the companies' market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.

However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Market Segmentation

By Drug Class (Revenue, USD Mn, 2021-2033)
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
By Dose Form (Revenue, USD Mn, 2021-2033)
- Solution
- Tablet
By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region: (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Nabriva Therapeutics
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals, Inc.
- Mylan N.V.
- Sanofi S.A.
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Dose Form
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis
Regulatory Scenario
New Product Launches
Collaborations and Agreements
Market Trends

4. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pleuromutilin Antibiotic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Glycylcycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Oxazolidinone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Ketolide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022 - 2033
North America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (US$ Mn)
  - South Africa
  - Central Africa
  - North Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Nabriva Therapeutics
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Paratek Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Melinta Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Allergan plc
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Lupin Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Dainippon Sumitomo Pharma
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Basilea Pharmaceutica International AG
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
  - Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

細菌性肺炎市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

細菌性肺炎市場：市場洞察、競爭格局及市場預測（2033 年）

FAQ

社區型細菌性肺炎 (CABP) 治療市場：按藥物類別、劑型、給藥途徑、分銷管道和地區分類